Pharmaceuticals

Global Small Molecule Targeted Therapy Market Size Projected to Reach $110.52 Billion During the Forecast Period

November 21, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Small Molecule Targeted Therapy Market Over The Five-Year Period 2025–2029?

The small molecule targeted therapy market has experienced substantial expansion in recent years. It is forecast to grow from $70.45 billion in 2024 to $77.29 billion in 2025, progressing at a compound annual growth rate (CAGR) of 9.7%. This historical growth can be attributed to the increasing availability of advanced diagnostic tools, a rising number of clinical trials, a heightened focus on treatments for oncology and rare diseases, an increase in regulatory approvals for innovative small molecule drugs, and a growing emphasis on combination therapies.

The small molecule targeted therapy market size is poised for robust expansion in the upcoming years. It is anticipated to grow to $110.52 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 9.4%. This projected growth during the forecast period can be attributed to the escalating prevalence of chronic and genetic diseases, the increasing acceptance of personalized medicine, growing investments in pharmaceutical research and development, heightened awareness among both healthcare professionals and patients, and rising government support and funding. Significant trends expected in this period include technological progress in drug design, advancements in high-throughput screening techniques, the development of precision medicine platforms, technology-driven enhancements in drug delivery systems, and the integration of genomics and proteomics data.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28332&type=smp

What Are The Top Growth Drivers Impacting The Small Molecule Targeted Therapy Market Outlook?

The increasing focus on tailored medical approaches is anticipated to fuel the expansion of the small molecule targeted therapy market in the future. Personalized medicine describes a medical strategy where prevention, diagnosis, and treatment are customized based on an individual’s genetic makeup, environmental influences, and lifestyle choices. The rise of personalized medicine stems from genomic advancements, which facilitate a more profound comprehension of unique genetic differences, thereby facilitating highly precise, focused treatments that enhance patient results and minimize experimental approaches in therapy. Small molecule targeted therapy facilitates personalized medicine through its ability to specifically pinpoint a patient’s distinct molecular or genetic disease characteristics, thereby boosting treatment effectiveness and mitigating adverse reactions. An illustration of this trend is observed in February 2024, where data from the Personalized Medicine Coalition, a US-based non-profit organization, indicated that in 2023, the FDA sanctioned 16 new personalized treatments for rare disease patients, an increase from six in 2022. Among the recently approved personalized treatments for 2023 were also seven cancer drugs and three for other diseases and conditions. Consequently, the heightened importance placed on personalized medicine is propelling the expansion of the small molecule targeted therapy market.

How Is The Small Molecule Targeted Therapy Market Segmented?

The small molecule targeted therapy market covered in this report is segmented as

1) By Type Of Therapy: Chemotherapy, Targeted Therapy, Immunotherapy

2) By Drug Class: Monoclonal Antibodies, Small Molecule Inhibitors, Combination Therapies

3) By Mechanism Of Action: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (Ahr) Modulators, Cell Cycle Inhibitors

4) By Disease Indication: Cancer, Autoimmune Diseases, Infectious Diseases

5) By Route Of Administration: Oral, Intravenous, Subcutaneous

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-microtubule Agents

2) By Targeted Therapy: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (AhR) Modulators

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies

Which Trends Are Impacting The Small Molecule Targeted Therapy Market?

Leading companies within the small molecule targeted therapy market are prioritizing the development of innovative solutions, such as oral small molecules, to enhance targeted delivery, improve patient compliance, and specifically address molecular pathways in oncology and other chronic conditions. An oral small molecule is a low-molecular-weight medication that can be administered orally, designed to easily enter cells and precisely target disease-related proteins or pathways. For example, in June 2025, Kura Oncology Inc., a US-based biotech company, secured FDA approval for a New Drug Application (NDA) for ziftomenib. This approval is for its use as a treatment for adult patients with relapsed or refractory acute myeloid leukemia (AML) with nucleophosmin 1 (NPM1) mutations. Ziftomenib is an oral targeted therapy specifically developed for adult patients presenting with relapsed or refractory AML carrying NPM1 mutations, thereby fulfilling a significant unmet medical requirement. It presents a positive safety profile and has demonstrated encouraging efficacy, including notable complete remission rates observed in clinical trials. By selectively inhibiting the menin-KMT2A interaction, ziftomenib effectively disrupts the growth of leukemic cells and introduces new therapeutic possibilities for this difficult-to-treat AML subtype.

Which Major Firms Are Strengthening Their Position In The Small Molecule Targeted Therapy Industry?

Major companies operating in the small molecule targeted therapy market are F. Hoffmann-La Roche AG (Roche), Merck KGaA, Pfizer Inc., Bayer AG, Sanofi S.A., Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, Blueprint Medicines Corporation, Kura Oncology Inc., G1 Therapeutics Inc., Ascentage Pharma Group International Inc., Rgenta Therapeutics Inc., Verastem Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/small-molecule-targeted-therapy-global-market-report

What Are The Regional Market Dynamics Impacting The Small Molecule Targeted Therapy Industry?

North America was the largest region in the small molecule targeted therapy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in small molecule targeted therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Small Molecule Targeted Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28332&type=smp

Browse Through More Reports Similar to the Global Small Molecule Targeted Therapy Market 2025, By The Business Research Company

Small Molecule Drug Discovery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report

Targeted Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Rna Targeting Small Molecules Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795